Maternal & Child Health Research Institute (MCHRI)
Showing 701-720 of 1,005 Results
-
Matthew Porteus
Sutardja Chuk Professor of Definitive and Curative Medicine
BioDr. Porteus was raised in California and was a local graduate of Gunn High School before completing A.B. degree in “History and Science” at Harvard University where he graduated Magna Cum Laude and wrote an thesis entitled “Safe or Dangerous Chimeras: The recombinant DNA controversy as a conflict between differing socially constructed interpretations of recombinant DNA technology.” He then returned to the area and completed his combined MD, PhD at Stanford Medical School with his PhD focused on understanding the molecular basis of mammalian forebrain development with his PhD thesis entitled “Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development.” After completion of his dual degree program, he was an intern and resident in Pediatrics at Boston Children’s Hospital and then completed his Pediatric Hematology/Oncology fellowship in the combined Boston Chidlren’s Hospital/Dana Farber Cancer Institute program. For his fellowship and post-doctoral research he worked with Dr. David Baltimore at MIT and CalTech where he began his studies in developing homologous recombination as a strategy to correct disease causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, he took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before again returning to Stanford in 2010 as an Associate Professor. During this time his work has been the first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients and is considered one of the pioneers and founders of the field of genome editing—a field that now encompasses thousands of labs and several new companies throughout the world. His research program continues to focus on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle. Clinically, Dr. Porteus attends at the Lucille Packard Children’s Hospital where he takes care of pediatric patients undergoing hematopoietic stem cell transplantation.
-
Manu Prakash
Associate Professor of Bioengineering, Senior Fellow at the Woods Institute for the Environment and Associate Professor, by courtesy, of Oceans
BioWe use interdisciplinary approaches including theory and experiments to understand how computation is embodied in biological matter. Examples include cognition in single cell protists and morphological computing in animals with no neurons and origins of complex behavior in multi-cellular systems. Broadly, we invent new tools for studying non-model organisms with significant focus on life in the ocean - addressing fundamental questions such as how do cells sense pressure or gravity? Finally, we are dedicated towards inventing and distributing “frugal science” tools to democratize access to science (previous inventions used worldwide: Foldscope, Abuzz), diagnostics of deadly diseases like malaria and convening global citizen science communities to tackle planetary scale environmental challenges such as mosquito surveillance or plankton surveillance by citizen sailors mapping the ocean in the age of Anthropocene.
-
Janey S.A. Pratt, MD
Clinical Professor, Surgery - Pediatric Surgery
BioDr. Janey S.A. Pratt, MD, FACS, FASMBS is a general surgeon who specializes in Laparoscopic and Robotic General and Metabolic and Bariatric Surgery (MBS). She began her career in general surgery at Massachusetts General Hospital, where she was a founding member of the MGH Weight Center. As surgical director she introduced minimally invasive MBS and adolescent MBS to MGH in 2001 and 2007 respectively. In 2011 Dr. Pratt took over as Director at the MGH Weight Center and continued to work on several national committees towards improving access and care for adolescents with severe obesity. Dr. Pratt continued to practice general surgery throughout her tenure at MGH seeing patients with breast cancer, hernias, and obesity. She performed advance minimally invasive surgery (MIS) as well as advanced endoscopy.
In 2016 Dr. Pratt moved to California where she began her work at Stanford University, splitting her time between the Lucille Packard Children’s Hospital and the Palo Alto VA. She performs Minimally Invasive MBS as well as endoscopy. Dr. Pratt has trained in robotic surgery as well. As a Clinical Professor of Surgery, Dr. Pratt is involved in training Stanford medical students and residents both in the OR, in clinic, in simulation labs and in the classroom. Since 2023 Dr. Pratt is dedicated only to the Children's Hospital running the Adolescent Metabolic and Bariatric Surgery program at LPCH. This is an MBSAQIP accredited program in a free-standing children's hospital dedicated to the multidisciplinary care of children with obesity. This program is one of the top 5 programs in the country. Dr. Pratt has been involved in creating and updated guidelines for Adolescent MBS since 2005. In 2018 she was first author on the ASMBS Pediatric Metabolic and Bariatric Surgery Guidelines. Her research interests include MIS MBS, pediatric obesity treatment and the use of medications to improve outcomes of MBS. Dr. Pratt frequently lectures on the subject of Adolescent Metabolic and Bariatric Surgery. -
Guillem Pratx
Associate Professor of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsThe Physical Oncology Lab is interested in making a lasting impact on translational cancer research by building novel physical tools and methods.
-
James Priest
Adjunct Clinical Assistant Professor, Pediatrics - Cardiology
Current Research and Scholarly InterestsThe Priest lab seeks a better understanding of the genetics and pathogenesis of congenital heart disease using translational genomics, big-data, and vertebrate models of cardiac development.
-
Lance Prince
Philip Sunshine, MD, Professor of Neonatology
BioLawrence (Lance) S. Prince, MD, PhD, is the Philip Sunshine Endowed Professor of Pediatrics at Stanford School of Medicine. Dr. Prince was previously a Professor of Pediatrics and Chief of the Division of Neonatology at the University of California, San Diego and Rady Children’s Hospital, San Diego.
Dr. Prince has a long and distinguished career mentoring clinical and scientific trainees and students, many of whom have gone on to establish their own successful careers as academic physician investigators. As a physician scientist, Dr. Prince leads a basic science laboratory focusing on the mechanisms regulating developmental immunology and lung injury and repair. Dr. Prince received a Bachelor of Science in Chemistry from University of Miami, an MD/PhD with a focus in Cell Biology from University of Alabama at Birmingham, and postdoctoral fellowship, Pediatrics residency, and Neonatal-Perinatal Medicine Fellowship training at the University of Iowa. Before arriving in California, Dr. Prince was an Associate Professor of Pediatrics at Vanderbilt University.
Dr. Prince’s research interests include the molecular and cellular mechanisms controlling lung development and the maturation of the fetal and neonatal immune systems. He has a particular clinical interest in managing and treating neonatal lung diseases, especially bronchopulmonary dysplasia (BPD) in babies born extremely preterm. Dr. Prince’s research team focuses primarily on the development of innate immunity during fetal life as it impacts health and disease in preterm infants. The laboratory is investigating how microbes including Group B streptococcus exploit the unique features of neonatal macrophages to avoid immune detection and cause disease, as well as leading a number of clinical and translational investigations. -
Charles G. Prober, MD
Professor of Pediatrics (Infectious Diseases) and, by courtesy, of Microbiology and Immunology
Current Research and Scholarly InterestsMy research interest is in the epidemiology, pathophysiology, prevention, and treatment of infections in children. Much of this research has focused on viral infections, especially those caused by herpes simplex virus (HSV). I have conducted a number of studies concerned with the epidemiology of HSV-2 infections in pregnant women, their partners, and neonates.
-
Judith Prochaska
Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Prochaska's clinical trials research focuses on developing and testing evidence-based interventions for tobacco, other substance use, physical activity, and diet. She has led randomized controlled trials of treatments that combine motivational, behavioral, and pharmacologic strategies, including use of telemedicine, therapeutic relational agents, social-media–supported interventions, and tailored programs for socio-demographically diverse and at-risk groups to advance population health.
-
Jochen Profit
Wendy J. Tomlin-Hess Endowed Professor
Current Research and Scholarly InterestsFunded by NIH R01 grants:
1) Development and application of composite measure of NICU quality - Baby-MONITOR
2) High reliability, safety culture and caregiver resilience as modifiers of care quality
3) Modifiable racial/ethnic disparities in quality of care delivery
4) Effectiveness of regionalized care delivery systems for preterm newborns -
Stephanie Pun, MD
Clinical Associate Professor, Orthopaedic Surgery
Current Research and Scholarly InterestsDr. Pun specializes in the treatment of complex hip disorders with surgical hip preservation options for children, adolescents, and adults. Her goal is to enhance hip function in active individuals and to prevent the early development of hip osteoarthritis.
-
Stanley Qi
Associate Professor of Bioengineering and, by courtesy, of Biomedical Data Science
BioStanley Qi (publishing as Lei S. Qi) is a pioneer in the field of genome engineering and the architect of the foundational technologies that transitioned CRISPR from a "cutting" tool into a universal platform for Programmable Biology. As the inventor of CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), Qi established the first methods for the precise, reversible, and targeted regulation of the human genome without altering the DNA sequence.
The Qi Lab integrates scalable genomic perturbation with live-cell and super-resolution imaging and computation-guided design to redefine the boundaries of cellular control. Under Dr. Qi’s leadership, the group has fundamentally expanded the genome engineering toolbox, evolving CRISPR from a single editing tool into a multidimensional platform for the precise control of dynamic and spatial cell states. This work includes establishing foundational technologies and architectures for precise epigenetic editing, multiplexed regulation of the transcriptome, programmable 3D genome organization, and spatial control of RNA logistics. By pioneering real-time visualization of chromatin dynamics and RNA in living cells, the lab provides an unprecedented window into the fundamental "control principles of life."
This principle-driven technology lineage has moved into the clinic, with the lab's compact epigenetic editor currently in first-in-human clinical testing for FSHD muscular dystrophy (NCT06907875). This milestone represents a core mission of the lab: translating foundational engineering into next-generation therapeutics that act predictably as dynamic, complex systems.
Beyond single-cell control, the Qi Lab is building a framework for synthetic cell–cell communication, with a particular emphasis on the bidirectional interplay between immune cells and neurons. The lab’s goal is to move beyond describing molecular parts to discovering fundamental control principles in living systems: how regulatory landscapes create stable states and memory, how spatial genome–RNA organization shapes dynamic responses, and how engineered cell–cell interactions can generate emergent multicellular behaviors.
By integrating computational design with experimental biology, Dr. Qi aims to identify the generalizable rules linking molecular programs to systems-level physiology. He is a Chan Zuckerberg Biohub Investigator and an Institute Scholar at the Sarafan ChEM-H, and is dedicated to shaping the technical and ethical frameworks that will define the future of human genome engineering. -
Xiaojie Qiu
Assistant Professor of Genetics and, by courtesy, of Computer Science
Current Research and Scholarly InterestsAt the Qiu Lab, our mission is to unravel and predict the intricacies of gene regulatory networks and cell-cell interactions pivotal in mammalian cell fate transitions over time and space, with a special emphasis on heart evolution, development, and disease. We are a dynamic and interdisciplinary team, harnessing the latest advancements in machine learning as well as single-cell and spatial genomics by integrating the predictive power of systems biology with the scalability of machine learning,
-
Thomas Quertermous, MD
William G. Irwin Professor of Cardiovascular Medicine
Current Research and Scholarly InterestsUnderstanding genetic basis of cardiovascular function and disease.
